Non-functional testing

Orchard Therapeutics Announces Comprehensive Presence at 19th Annual WORLDSymposium

Retrieved on: 
Wednesday, February 8, 2023
Diagnosis, Non-functional testing, CGMP, Metabolism, Therapy, MLD, Poster, Date-time group, WORLD, Patient, Union, Clinical trial, HSC, 2021 Essex County Council election, Research, Pharmaceutical industry, Vaccine, Fur clothing, Medical imaging, Communications satellite, Flour

BOSTON and LONDON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced a series of presentations from across its neurometabolic portfolio will be featured at the 19th Annual WORLDSymposium taking place February 22-26, 2023, in Orlando, Florida.

Key Points: 
  • BOSTON and LONDON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced a series of presentations from across its neurometabolic portfolio will be featured at the 19th Annual WORLDSymposium taking place February 22-26, 2023, in Orlando, Florida.
  • “The data to be presented at WORLD 2023 represents significant progress toward our mission of ending the devastation of severe genetic diseases though the transformative potential of HSC gene therapy,” said Leslie Meltzer, Ph.D., chief medical officer of Orchard Therapeutics.
  • Oral presentation details are as follows (all times in EST; * denotes corresponding poster):
    Date/Time: Friday, February 24 at 8:00 a.m.
  • Title: A MLD newborn screening pilot-study for metachromatic leukodystrophy in Germany: Results of the first 12 months
    Date/Time: Saturday, February 25 from 4:00-5:00 p.m.
    Date/Time: Saturday, February 25 from 4:00-5:00 p.m.

Gemini partners with UroGPO, a Specialty Networks Company

Retrieved on: 
Wednesday, January 18, 2023
Atmos, Partnership, Senior, Eurosport 1, Patient, Non-functional testing, Urodynamic testing, Physician, Health insurance

Boca Raton, FL, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Gemini Medical Technologies, a privately held U.S.-based urodynamics diagnostics manufacturer, announced a new partnership today with UroGPO, a Specialty Networks Company, that will give urologists a new option for diagnostic testing.

Key Points: 
  • Boca Raton, FL, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Gemini Medical Technologies, a privately held U.S.-based urodynamics diagnostics manufacturer, announced a new partnership today with UroGPO, a Specialty Networks Company, that will give urologists a new option for diagnostic testing.
  • “UroGPO and Specialty Networks have recognized an increased need for our members to gain access to new options, specifically in the Urodynamic catheter market.
  • As such, we have responded with developing what we believe is an extremely beneficial partnership with Gemini on their Atmos product line.
  • We are pleased to add Gemini and their Atmos product line to the list of UroGPO industry partners and products.” said Darren J Dieleman, Senior Vice President of Specialty Networks, LLC.

Allison Transmission Collaborates with Nikola to Drive Next-Generation Vehicle Development at Allison’s Vehicle Electrification + Environmental Test Center

Retrieved on: 
Wednesday, January 11, 2023
Environment, Other Transport, Technology, EV, Electric Vehicles, Automotive, HVAC, Transport, Automotive Manufacturing, Manufacturing, Batteries, Transport, Nikola, Vehicle electrification, Allison, FCEV, Allison Transmission, Transmission, Original equipment manufacturer, BEV, Nikola Corporation, Non-functional testing, TRE, Multimedia, HVAC, Rail transport

Allison Transmission has partnered with Nikola Corporation , a global leader in zero-emissions transportation and energy supply and infrastructure solutions, to conduct testing of its Class 8 battery-electric vehicle (BEV) and hydrogen fuel cell electric vehicle (FCEV) at Allison’s state-of-the-art Vehicle Electrification + Environmental Test (VE+ET) Center.

Key Points: 
  • Allison Transmission has partnered with Nikola Corporation , a global leader in zero-emissions transportation and energy supply and infrastructure solutions, to conduct testing of its Class 8 battery-electric vehicle (BEV) and hydrogen fuel cell electric vehicle (FCEV) at Allison’s state-of-the-art Vehicle Electrification + Environmental Test (VE+ET) Center.
  • View the full release here: https://www.businesswire.com/news/home/20230111005183/en/
    Allison Transmission collaborated with Nikola to test its Class 8 battery-electric vehicle and hydrogen fuel cell electric vehicle through controlled thermal environments and dynamometer road simulations at Allison’s state-of-the-art Vehicle Electrification + Environmental Test Center in Indianapolis.
  • (Photo: Business Wire)
    “We’re proud to collaborate with Nikola as they develop innovative, next-generation vehicles designed to reduce emissions and optimize performance,” said David Proctor, General Manager, Allison Vehicle Electrification + Environmental Test Center.
  • The Vehicle Electrification + Environmental Test Center provides several benefits for OEMs including the ability to conduct testing in a safe, controlled, consistent environment which enables secure, dependable, repeatable results.

ICCPP, Parent Company of VOOPOO, Achieves Milestone with Its EVEREST LAB Accredited by China National Accreditation Service

Retrieved on: 
Sunday, January 22, 2023
Certification, Accreditation, Laboratory, TPD, ILAC, PCT, CNAS, SCI, National Intellectual Property Rights Coordination Center, International Laboratory Accreditation Cooperation, Intellectual property, Lab, Specialization, Research, Non-functional testing, Republic, Medical device, EU

CNAS is the only institution in China qualified to issue national laboratory accreditation certificates approved and authorized by the Certification and Accreditation Administration of the People's Republic of China.

Key Points: 
  • CNAS is the only institution in China qualified to issue national laboratory accreditation certificates approved and authorized by the Certification and Accreditation Administration of the People's Republic of China.
  • Established at the end of 2021, the EVEREST Lab is committed to becoming a cutting-edge scientific research platform in the world.
  • The Lab is established and developed with technical standards higher than those of the global industry and regulatory units.
  • In addition to basic theoretical research, the EVEREST Lab also attaches great importance to the industrial application of cutting-edge technology.

Telehealth Requires the Right Technology to Deliver the Right Care

Retrieved on: 
Tuesday, December 20, 2022
Medical education, Digital technology, Patient, MOME, Communication, Campion, Wireless, Mayo Clinic, ARC, Plague, Transport, COVID-19, Non-functional testing, FDA, Deep learning, Economics, Jawaharlal Institute of Postgraduate Medical Education and Research, Telehealth, Telemetry, Helwig, Artificial intelligence, Physician, Cardiovascular disease, Cardiology, Mayo, Clinical professor, Medical device, Pharmaceutical industry, Research

WALTHAM, Mass., Dec. 20, 2022 /PRNewswire-PRWeb/ --  In 2021, the Mayo Clinic conducted the COVID-19 Telehealth Impact Study to analyze the "natural experiment of telehealth adoption during the pandemic." The study ultimately supports the widespread clinical adoption of telehealth while recommending continued improvements in the technology that delivers it.(1) To that end, the Mayo Clinic's Department of Cardiovascular Medicine, one of the largest in the world, has partnered with InfoBionic by incorporating its MoMe Kardia remote cardiac monitoring platform for its clinicians and patients around the world.(2)

Key Points: 
  • Finding the right technology to manage acute care will be critical to the future of telehealth.
  • The study ultimately supports the widespread clinical adoption of telehealth while recommending continued improvements in the technology that delivers it.
  • (2)
    After reviewing 2 billion medical claims for telehealth care, researchers from the Mayo Clinic acknowledge that telehealth is an effective tool for healthcare delivery.
  • During the first few months of the COVID-19 pandemic, telehealth visits at the Mayo Clinic increased by 10,880%.

Global Fluorescent in Situ Hybridization Probe Market Report to 2027: Featuring Thermo Fisher Scientific, Roche Holdings, PerkinElmer and Sysmex Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, December 9, 2022
Genetics, Health, Oncology, IVD, Autism, Environment, Microdeletion syndrome, Diagnosis, Leukemia, Research, Non-functional testing, Birth, Disability in Canada, Incidence, Cancer, Government, Growth, Flow-FISH, Ageing, Application, Medical device, Medical imaging, FISH

In 2021, instrument/ software segment held a major share in the market.

Key Points: 
  • In 2021, instrument/ software segment held a major share in the market.
  • By Technology: The report provides the bifurcation of the market into three segments based on the technology: Q FISH, Flow FISH and others.
  • In 2021, Q FISH technology segment held a major share in the market.
  • By Application: The report provides the bifurcation of the market into two segments based on the application: cancer diagnostics and other.

NowSecure Launches Mobile Pen Testing-as-a-Service (PTaaS) to Scale Security More Efficiently

Retrieved on: 
Tuesday, December 6, 2022
James Cullen (PTAA), SOC 2, Trust, Ciso Morales, ADA, Google Play, AT&T, Security, AT, Automation, TAG, Privacy, Gartner, Non-functional testing, Uber, Caribou Coffee, SOC, OWASP, Policy, IRobot, Risk, App Store (iOS/iPadOS), Multimedia, Documentation, Application, Organization, IDC, VPN, NIAP, NowSecure, Instrumentation, Medical device, Online shopping, Chime, L2

CHICAGO, Dec. 6, 2022 /PRNewswire/ -- NowSecure, the leading standards-based mobile app security and privacy software company, today launched its latest offering, NowSecure Mobile Pen Testing as a Service (PTaaS), to bridge the gap between automated and manual mobile security assessments for continuous security. Designed to provide mobile developers and security teams with a more cost-effective, efficient pen testing solution, NowSecure PTaaS combines periodic expert manual assessments with automated continuous testing to optimize for full coverage at a higher frequency rate. With this combination, the all-in-one portal and service can quickly identify issues earlier in the developer pipeline and provide consultative guidance to rapidly remediate security issues and speed deployment of high-quality software into production.

Key Points: 
  • NowSecure Mobile PTaaS bridges the gap between automated and manual mobile security assessments for continuous security.
  • By integrating NowSecure Mobile PTaaS, CISOs and security leaders can streamline their pen testing budget while prioritizing continuous, full coverage security testing.
  • NowSecure Mobile PTaaS joins the industry's only full suite of mobile app security solutions from NowSecure including NowSecure Platform for automated security testing, NowSecure Workstation kit for pen tester productivity, NowSecure Supply Chain Risk Management , NowSecure Pen Testing Services , and NowSecure Academy training courseware for dev and security teams.
  • The most demanding organizations depend on NowSecure for its extensive security testing solution suite for DevSecOps, Pen Testing as a Service (PTaaS), mobile app supply-chain monitoring, expert mobile pen testing and training courseware.

Singapore Emerges as IVD Leader in APAC Region, finds Kalorama Information

Retrieved on: 
Monday, December 5, 2022
Knowledge, Biotechnology, Degenerative disease, IVD, GDP, World Bank, POC, Virology, Prevalence, Cancer, Non-functional testing, Unemployment, Microbiology, Diabetes, Medicine, Government, COVID-19, Death, Ageing, Knowledge-centered support, Life expectancy, Medical device, Pharmaceutical industry, Science

ARLINGTON, Va., Dec. 5, 2022 An aging and higher-income regionally population are the main factors boosting Singapore as an in vitro diagnostic (IVD) market, according to Kalorama Information.

Key Points: 
  • ARLINGTON, Va., Dec. 5, 2022 An aging and higher-income regionally population are the main factors boosting Singapore as an in vitro diagnostic (IVD) market, according to Kalorama Information.
  • The medical market researcher recently published a report on the region, In Vitro Diagnostics (IVD) in Malaysia, Singapore and Indonesia, 2022 .
  • The firm found that Singapore is one of the most prosperous nations in the APAC region and that extends to its in vitro diagnostics market.
  • Kalorama Information, part of Science and Medicine Group, is the leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), biotechnology, medical devices, and pharmaceuticals.

Children's Hospital of Philadelphia Celebrates 5,000 Deliveries in Garbose Family Special Delivery Unit

Retrieved on: 
Wednesday, November 30, 2022
Growth, Fetus, Children's Hospital of Philadelphia, Diagnosis, SCT, Electrical telegraph, Gastroschisis, Ventricular septal defect, Hospital, Mother, Garbose Building, Non-functional testing, Health, Physician, CGC, Neoplasm, Omphalocele, Spina bifida, Birth, Parent, Prussia, Congenital diaphragmatic hernia, Harriet, Hydrops, CFDT, Birth defect, Research, Delivery unit, SDU, CHOP, Woman, Surgeon, Sacrococcygeal teratoma, Dentistry, Toy, Medical imaging, MD, Child, Lyra, Treatment

PHILADELPHIA, Nov. 30, 2022 /PRNewswire/ -- More than 14 years after opening the Garbose Family Special Delivery Unit (SDU), the world's first birth facility exclusively for mothers carrying babies with known birth defects, Children's Hospital of Philadelphia (CHOP) is celebrating its 5,000th delivery.

Key Points: 
  • PHILADELPHIA, Nov. 30, 2022 /PRNewswire/ -- More than 14 years after opening the Garbose Family Special Delivery Unit (SDU), the world's first birth facility exclusively for mothers carrying babies with known birth defects, Children's Hospital of Philadelphia (CHOP) is celebrating its 5,000th delivery.
  • "Traditionally, these mothers will give birth in one hospital, and their newborn will be transferred to a specialized pediatric hospital shortly after delivery.
  • "The Garbose Special Delivery Unit is a very important part of the comprehensive care our Center for Fetal Diagnosis and Treatment is able to provide."
  • About Children's Hospital of Philadelphia:A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital.

Now, Enterprise Compliance and Development Teams can Learn Digital Accessibility Best Practices On-the-Fly from Industry Experts with A11yAcademy™ Built-in Training

Retrieved on: 
Monday, November 28, 2022
Internet, ESG, Section 508 Amendment to the Rehabilitation Act of 1973, SME, Machine learning, Artificial intelligence, Curriculum, Crowdsourcing, Non-functional testing, WCAG, Disability, Software as a service, ADA, Biophysical environment, ROI, Online shopping

PHILADELPHIA, Nov. 28, 2022 /PRNewswire/ -- Premiere digital accessibility SaaS technology company Allyable introduces A11yAcademy™—the industry's first built-in, real-time compliance education tool—as an integral component of its best-selling digital accessibility project management platform, A11yAble360™.

Key Points: 
  • PHILADELPHIA, Nov. 28, 2022 /PRNewswire/ -- Premiere digital accessibility SaaS technology company Allyable introduces A11yAcademythe industry's first built-in, real-time compliance education toolas an integral component of its best-selling digital accessibility project management platform, A11yAble360.
  • A11yAcademy puts the collective expertise of industry specialists at the fingertips of internal development and compliance teams, helping to close the learning gap about digital accessibility regulations and best-practice remediations.
  • Its comprehensive, built-in curriculum covers all key topics of digital accessibility knowledge, such as Accessibility Fundamentals, Compliance Testing, Designing for Accessibility, Manual & Automatic Remediation, and specific guidelines for WCAG (Web Content Accessibility Guidelines)2.1 AA, EU341509, Section 508, ADA, and other global criteria.
  • Allyable is the only DOBE-certified digital accessibility supplier in the industry.